MYB and non-small cell lung carcinoma: In an attempt to expand the spectrum of potential MYB inhibitors we have discovered Bcr-TMP as a nanomolar-active MYB-inhibitory compound, which was described before as a potent caspase activator in human breast and non-small-cell lung cancer cells [61].